LRRC15 and neoplasm: This approach killed nearly all of the local bladder and pancreatic tumour cells and diminished CAF numbers, prolonging survival and efficiently ameliorating metastasis in preclinical models.105 Leucine-rich-repeat-containing 15 (LRRC15)+ CAFs have also been targeted using a LRRC15-antibody drug conjugate (ABBV-085) to deliver the potent anti-mitotic drug monomethyl auristatin E (MMAE) in PDX models of NSCLC-adenocarcinoma, osteocarcinoma, breast cancer and glioblastoma, significantly reducing tumour volume.